Literature DB >> 7202858

Comparison of clinical couse and sequential electrophysiological tests in diabetics with symptomatic polyneuropathy and its implications for clinical trials.

D A Greene, M J Brown, S N Braunstein, S S Schwartz, A K Asbury, A I Winegrad.   

Abstract

The use of electrophysiological (EP) tests as the primary basis for determining outcome in clinical trials of therapy for symptomatic diabetic polyneuropathy, and the frequently short duration of such trials, is based on assumptions at variance with the pathology and natural history of this disorder and with the evidence that the commonly employed EP tests predominantly reflect the status of the large myelinated nerve fibers. The course of painful, distal symmetrical, primarily sensory polyneuropathy was studied in nine chronic diabetics, aged 21--59 yr, selected for the absence of other forms of diabetic neuropathy, other causes of neuropathy, and other significant illness. All were treated with modifications of diet, insulin, and a daily multivitamin tablet, and, on a randomized basis, also received either placebo or myo-inositol tablets. Initially, and after 2, 4, and 6 mo, a standardized questionnaire was used to assess symptoms, and a standardized neurological examination and battery of EP tests were performed. A minimum of 6 mo was found necessary to assess the clinical course of this syndrome. Clinical improvement occurred in both legs and arms in four patients, as judged by improvement both in symptoms and in the extent of deficits in pinprick and temperature perception; abnormalities in sensory modalities mediated by large myelinated fibers, however, were generally unaltered after 6 mo. A nonuniform distribution of abnormal EP tests of sensory components of the commonly studied nerves of the leg and arm was demonstrated in the study group at the outset, and clinical improvement was not accompanied by evidence of any consistent pattern of improvement in the initially abnormal EP tests. A significant fraction of chronic diabetics with painful, distal symmetrical, primarily sensory polyneuropathy selected by standard criteria appear to have potential for clinical improvement over 6 mo, but primarily in sensory modalities that make it inappropriate to use the common EP tests as the primary basis of judging outcome.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7202858     DOI: 10.2337/diab.30.2.139

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  19 in total

1.  Hyperalgesia in spontaneous and experimental animal models of diabetic neuropathy.

Authors:  L Wuarin-Bierman; G R Zahnd; F Kaufmann; L Burcklen; J Adler
Journal:  Diabetologia       Date:  1987-08       Impact factor: 10.122

2.  Quantitation of skin vasomotor control in normal subjects and in diabetic patients with autonomic neuropathy.

Authors:  A F Donk; T J Faes; D Broere; E A van der Veen; F W Bertelsmann
Journal:  J Neurol       Date:  1990-12       Impact factor: 4.849

3.  Inositol has behavioral effects with adaptation after chronic administration.

Authors:  H Cohen; M Kotler; Z Kaplan; M A Matar; O Kofman; R H Belmaker
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

Review 4.  The biochemistry of diabetes.

Authors:  R Taylor; L Agius
Journal:  Biochem J       Date:  1988-03-15       Impact factor: 3.857

5.  The correlation between sensory nerve conduction velocities and three metabolic indices in rats treated with streptozotocin.

Authors:  P O Julu
Journal:  Diabetologia       Date:  1988-04       Impact factor: 10.122

Review 6.  The diabetic leg.

Authors:  J D Ward
Journal:  Diabetologia       Date:  1982-03       Impact factor: 10.122

7.  The Therapeutic Role of Gangliosides in Neurological Disorders.

Authors:  J S Schneider
Journal:  CNS Drugs       Date:  1994-03       Impact factor: 5.749

8.  Prevalence and forms of neuropathic morbidity in 800 diabetics.

Authors:  J A O'Hare; F Abuaisha; M Geoghegan
Journal:  Ir J Med Sci       Date:  1994-03       Impact factor: 1.568

9.  The natural history of acute painful neuropathy in diabetes mellitus.

Authors:  A G Archer; P J Watkins; P K Thomas; A K Sharma; J Payan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-06       Impact factor: 10.154

Review 10.  The efficacy of aldose reductase inhibitors in the management of diabetic complications. Comparison with intensive insulin treatment and pancreatic transplantation.

Authors:  J M van Gerven; A M Tjon-A-Tsien
Journal:  Drugs Aging       Date:  1995-01       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.